SASPject PT 3.9
Alternative Names: PT 3.9; SASPject™ PT 3.9Latest Information Update: 20 Nov 2025
At a glance
- Originator Phico Therapeutics
- Class Antibacterials; Bacteriophages; DNA-binding proteins; Gene therapies
- Mechanism of Action Bacterial DNA inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Pseudomonal infections
Most Recent Events
- 20 Nov 2025 SASPject PT 3.9 is still in preclinical development in Pseudomonal-infections in United Kingdom (IV) (Phico Therapeutics pipeline, November 2025)
- 28 May 2025 No recent reports of development identified for preclinical development in Pseudomonal-infections in United Kingdom (IV)
- 19 Apr 2021 Preclinical development in Pseudomonal infections in United Kingdom before April 2021 (IV)